[go: up one dir, main page]

MX2019001228A - Metodo de produccion del compuesto de pirazol-amida. - Google Patents

Metodo de produccion del compuesto de pirazol-amida.

Info

Publication number
MX2019001228A
MX2019001228A MX2019001228A MX2019001228A MX2019001228A MX 2019001228 A MX2019001228 A MX 2019001228A MX 2019001228 A MX2019001228 A MX 2019001228A MX 2019001228 A MX2019001228 A MX 2019001228A MX 2019001228 A MX2019001228 A MX 2019001228A
Authority
MX
Mexico
Prior art keywords
production method
pyrazole
amide compound
compound
salt
Prior art date
Application number
MX2019001228A
Other languages
English (en)
Inventor
Yamamoto Hiroshi
Inaba Takashi
Yamasaki Takahiro
Motomura Takahisa
Inoue Masafumi
Ito Hirotsugu
Matsuo Takuya
Suzawa Koichi
Takeichi Tsubasa
Kajimoto Yasuyuki
Ito Takao
Ikemoto Yukishige
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2019001228A publication Critical patent/MX2019001228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0231—Halogen-containing compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235—Nitrogen containing compounds
    • B01J31/0244—Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método de producción de un compuesto representado por la formula [I] (ver formula) o una sal farmacéuticamente aceptable del mismo, o un hidrato 5 del mismo.
MX2019001228A 2016-07-29 2017-07-28 Metodo de produccion del compuesto de pirazol-amida. MX2019001228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016150657 2016-07-29
PCT/JP2017/027358 WO2018021508A1 (ja) 2016-07-29 2017-07-28 ピラゾール－アミド化合物の製造方法

Publications (1)

Publication Number Publication Date
MX2019001228A true MX2019001228A (es) 2019-06-03

Family

ID=61017374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001228A MX2019001228A (es) 2016-07-29 2017-07-28 Metodo de produccion del compuesto de pirazol-amida.

Country Status (12)

Country Link
US (1) US10981877B2 (es)
EP (1) EP3492452B1 (es)
JP (1) JP7036724B2 (es)
KR (1) KR20190036549A (es)
CN (2) CN109476609B (es)
AU (1) AU2017303898B2 (es)
BR (1) BR112019001447A2 (es)
CA (1) CA3031621A1 (es)
IL (1) IL264307B (es)
MX (1) MX2019001228A (es)
RU (1) RU2736722C2 (es)
WO (1) WO2018021508A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001228A (es) * 2016-07-29 2019-06-03 Japan Tobacco Inc Metodo de produccion del compuesto de pirazol-amida.
AU2019214048B2 (en) * 2018-02-01 2023-03-16 Japan Tobacco Inc. Nitrogenated heterocyclic amide compound, and use thereof for medical purposes
WO2020054734A1 (ja) 2018-09-11 2020-03-19 日本たばこ産業株式会社 ピラゾール－アミド化合物を含有する慢性腎臓病の治療又は予防剤
CN113490492B (zh) * 2019-03-04 2024-09-27 日本烟草产业株式会社 吡唑酰胺化合物的非晶质固体分散体
KR102769218B1 (ko) * 2022-09-28 2025-02-24 주식회사 제이디바이오사이언스 신규한 플루오렌 유도체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2827285B1 (fr) 2001-07-10 2003-12-05 Rhodia Chimie Sa Reactif et procede pour la perfluoroalcoylation
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CA2537079A1 (en) 2004-02-20 2005-09-01 Astellas Pharma Inc. Fluorene derivative
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
AU2010240142A1 (en) 2009-04-22 2011-11-10 Astellas Pharma Inc. Carboxylic acid compound
CN102822148B (zh) 2010-03-31 2015-03-11 东丽株式会社 纤维肌痛综合征的治疗剂或预防剂
CN108929333A (zh) * 2013-03-13 2018-12-04 豪夫迈·罗氏有限公司 制备苯并氧氮杂*化合物的方法
ES2663789T3 (es) * 2013-03-15 2018-04-17 Japan Tobacco, Inc. Compuesto de pirazol-amida y usos medicinales del mismo
JP2014198712A (ja) * 2013-03-15 2014-10-23 日本たばこ産業株式会社 フルオレン化合物の水和物、およびその結晶
US20150018403A1 (en) * 2013-07-01 2015-01-15 Japan Tobacco Inc. Fluorene-amide compounds and pharmaceutical use thereof
WO2015002119A1 (ja) * 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール－アルコール化合物およびその医薬用途
MX2019001228A (es) * 2016-07-29 2019-06-03 Japan Tobacco Inc Metodo de produccion del compuesto de pirazol-amida.

Also Published As

Publication number Publication date
CN114716377A (zh) 2022-07-08
RU2019105577A3 (es) 2020-08-31
AU2017303898B2 (en) 2021-01-21
EP3492452A4 (en) 2019-12-25
EP3492452A1 (en) 2019-06-05
US10981877B2 (en) 2021-04-20
BR112019001447A2 (pt) 2019-05-07
WO2018021508A1 (ja) 2018-02-01
US20190375717A1 (en) 2019-12-12
JP7036724B2 (ja) 2022-03-15
CN109476609A (zh) 2019-03-15
IL264307B (en) 2021-04-29
AU2017303898A1 (en) 2019-01-31
CA3031621A1 (en) 2018-02-01
EP3492452B1 (en) 2022-08-31
CN109476609B (zh) 2022-06-14
RU2736722C2 (ru) 2020-11-19
KR20190036549A (ko) 2019-04-04
JPWO2018021508A1 (ja) 2019-05-23
RU2019105577A (ru) 2020-08-31

Similar Documents

Publication Publication Date Title
JOP20200225A1 (ar) مشتق كوينولين عالي النقاء وطريقة لإنتاجه
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12019500480A1 (en) Pyridine compound
PH12017501523A1 (en) Selective bace1 inhibitors
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX2015017156A (es) Inhibidores de bace.
MX2019001228A (es) Metodo de produccion del compuesto de pirazol-amida.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MY183123A (en) Synthesis of copanlisib and its di hydrochloride salt
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
MY193239A (en) Novel b-lactamase inhibitors
MX385672B (es) Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida.
PH12018500999A1 (en) Sodium channel blocker
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
PH12017500435B1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
MX2020004972A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia.
MX2019000984A (es) Proceso para preparacion de indanonas.
IN2014MU00072A (es)
IN2014MU00071A (es)
IN2014MU00070A (es)
IN2014MU00566A (es)